<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04526132</url>
  </required_header>
  <id_info>
    <org_study_id>BALF-PAIN-3001</org_study_id>
    <nct_id>NCT04526132</nct_id>
  </id_info>
  <brief_title>A Phase Ⅲ Clinical Study Trial of Felbinac Trometamol Injection in China</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Placebo Parallel Controlled Phase Ⅲ Clinical Trial on the Efficacy and Safety of Felbinac Trometamol Injection in the Treatment of Moderate and Severe Postoperative Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shijiazhuang Yiling Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shijiazhuang Yiling Pharmaceutical Co. Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multi-center, randomized, double-blind, placebo parallel controlled phase Ⅲ clinical trial&#xD;
      on the efficacy and safety of felbinac trometamol Injection in the treatment of moderate and&#xD;
      severe postoperative pain.main purpose is to evaluate the efficacy of Felbinac Trometamol&#xD;
      Injection in the treatment of moderate and severe pain after surgery.Secondary purpose is to&#xD;
      evaluation the safety of Felbinac Trometamol Injection in the treatment of moderate and&#xD;
      severe pain after surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">September 14, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24h total morphine consumption</measure>
    <time_frame>up to 24hours after multi-dose</time_frame>
    <description>The the total amount of morphine within 24 hours after the end of first drug administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the pain intensity curve(AUC)</measure>
    <time_frame>up to 24 hours after multi-dose</time_frame>
    <description>Pain intensity under exercise/rest state - area under the time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Press time</measure>
    <time_frame>up to 24 hours after multi-dose</time_frame>
    <description>The first time to press the analgesic pump for analgesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of analgesia pump presses</measure>
    <time_frame>up to 24 hours after multi-dose</time_frame>
    <description>Total number of analgesic pump presses within 24 hours after the first dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of effective presses of analgesia pump</measure>
    <time_frame>up to 24 hours after multi-dose</time_frame>
    <description>The number of effective presses of analgesia pump within 24 hours after the end of the first dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of using morphine to remedy analgesia</measure>
    <time_frame>up to 24 hours after multi-dose</time_frame>
    <description>Proportion of using morphine to remedy analgesia within 24 hours after the first dose</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">336</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Experimental: group1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Generic name: Felbinac Trometamol Injection; Placebo:Normal saline Dosage form: Injection Dosage:8ml Volume:4ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: group2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Generic name:Placebo Placebo:Normal saline Dosage form:Injection Dosage:8mg Volume:4ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Felbinac Trometamol Injection</intervention_name>
    <description>Felbinac Trometamol Injection diluted to 100 ml with 0.9% sodium chloride injection.Use a micro-injection pump to inject intravenously at a constant speed for 30 min (± 2 min)..&#xD;
One dose at 8h and 16h after the start of the first dose,the first intravenous infusion was started at the end of the operation (Skin suture completes the last stitch).The drug was given 3 times,3 times/day,once every 8 hours.</description>
    <arm_group_label>Experimental: group1</arm_group_label>
    <other_name>4-Biphenylacetic Acid Trishydroxymettiylaminometnane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebo diluted to 100 ml with 0.9% sodium chloride injection.Use a micro-injection pump to inject intravenously at a constant speed for 30 min (± 2 min).&#xD;
One dose at 8h and 16h after the start of the first dose,the first intravenous infusion was started at the end of the operation (Skin suture completes the last stitch).The drug was given 3 times,3 times/day,once every 8 hours.</description>
    <arm_group_label>Experimental: group2</arm_group_label>
    <other_name>Normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18≤age≤65 years of age, gender is not limited;&#xD;
&#xD;
          -  ASA grade I or II;&#xD;
&#xD;
          -  18 ≤ body mass index (BMI) ≤ 30 [BMI = weight (kg) / height 2 (m2)];&#xD;
&#xD;
          -  Expected hospital stay ≥48 hours after surgery；&#xD;
&#xD;
          -  Patients planned to receive open or laparoscopic upper abdominal surgery (such as&#xD;
             gallbladder surgery, stomach surgery, etc.) with a single surgical incision ≥5 cm,&#xD;
             thoracotomy or thoracoscopic chest surgery (such as lung lobe resection surgery, lung&#xD;
             wedge resection surgery, etc.),both under general anesthesia.Inpatients who underwent&#xD;
             open surgery under upper abdominal general anesthesia (including a single surgical&#xD;
             incision ≥ 5 cm and Thoracic or thoracoscopic surgery;&#xD;
&#xD;
          -  Expected to require more than 24 hours of PCIA ( patient controlled intravenous&#xD;
             analgesia) treatment after surgery ;surgery;&#xD;
&#xD;
          -  Ability to understand research procedures and pain scales, operate PCIA devices, and&#xD;
             communicate effectively with researchers;&#xD;
&#xD;
          -  Agree to participate in the trial and voluntarily sign the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Except for the chronic pain caused by the target lesion of this operation, those who&#xD;
             have a history of chronic pain for more than 3 months or who are undergoing regular&#xD;
             analgesia for more than 3 months;&#xD;
&#xD;
          -  Those who have used barbiturates within 20 days before surgery, those who used other&#xD;
             analgesics, muscle relaxants or sedatives within 24 hours before operation (excluding&#xD;
             those required for this operation), or those who used long-acting non-steroidal&#xD;
             anti-inflammatory drugs (NSAIDs) within 12 hours, or those who used short-acting&#xD;
             non-steroidal anti-inflammatory drugs (NSAIDs) within 6 hours before operation(See&#xD;
             Annex 1).&#xD;
&#xD;
          -  A person with high bleeding risk, and also including who with congenital bleeding&#xD;
             disorders (such as hemophilia), thrombocytopenia (PLT &lt; 80 × 10 ∧ 9 / L), abnormal&#xD;
             platelet function (such as idiopathic thrombocytopenic purpura, disseminated&#xD;
             intravascular coagulation, congenital platelet dysfunction, etc.) or any clinically&#xD;
             significant active bleeding, coagulopathy;&#xD;
&#xD;
          -  A person who received full-dose anticoagulant therapy, activated protein C or&#xD;
             thrombolytic drugs within 6 hours before surgery (except for heparin subcutaneous&#xD;
             injection for preventive treatment);&#xD;
&#xD;
          -  People with heart failure (NYHA grade III or IV), unstable angina pectoris, acute&#xD;
             myocardial infarction, and severe arrhythmia within 6 months before surgery&#xD;
&#xD;
          -  Hypertensive patients who have not been satisfactorily controlled by blood pressure&#xD;
             (systolic blood pressure ≥160mmHg or diastolic blood pressure ≥105mmHg), or&#xD;
             ACEI/diuretics for ≥30 days, or hypotension (systolic blood pressure &lt;90mmHg);&#xD;
&#xD;
          -  People with pulmonary fibrosis bronchial asthma, pulmonary heart disease or other&#xD;
             serious respiratory diseases that are not the purpose of this treatment;&#xD;
&#xD;
          -  Person with gastrointestinal ulcer and a history of gastrointestinal bleeding 6 weeks&#xD;
             before operation and required medical treatment(prophylactic medication or undiagnosed&#xD;
             persons are not excluded);&#xD;
&#xD;
          -  Those with previous cerebral arteriovenous malformations, cerebral aneurysms, brain&#xD;
             tumors, or preoperative traumatic brain injury, intracranial surgery, history of&#xD;
             stroke;&#xD;
&#xD;
          -  Patients with poor glycemic control of diabetes (random blood glucose &gt; 11.1mmol / L);&#xD;
&#xD;
          -  Patients with autoimmune diseases, connective tissue diseases, etc. who need long-term&#xD;
             use of adrenocortical hormone therapy;&#xD;
&#xD;
          -  Abnormal liver and kidney function: ALT/AST&gt; 2 times the upper limit of normal value,&#xD;
             or creatinine&gt; upper limit of normal value, or dialysis treatment within 28 days&#xD;
             before surgery;&#xD;
&#xD;
          -  Allergic constitution, or known to be allergic to this drug, NSAIDs, and opioids;&#xD;
&#xD;
          -  Patients who are afflicted with narcotic drugs, drugs, or resistant to opioids;&#xD;
&#xD;
          -  A woman who is breast-feeding or pregnant, who is unable or unwilling to follow the&#xD;
             investigator's guidance during the study period and within 3 months after the last&#xD;
             study treatment;&#xD;
&#xD;
          -  Those who have participated in other clinical trials within 3 months before surgery;&#xD;
&#xD;
          -  Investigators believe that it is not suitable for participating in this research.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wen Ouyang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Third Xiangya Hospital of Central South University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shijiazhuang Yiling Pharmaceutical Co.,Ltd</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050036</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 21, 2020</study_first_submitted>
  <study_first_submitted_qc>August 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2020</study_first_posted>
  <last_update_submitted>August 21, 2020</last_update_submitted>
  <last_update_submitted_qc>August 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biphenylylacetic acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

